Clinical outcomes of patients with corticosteroid refractory immune checkpoint inhibitor-induced enterocolitis treated with infliximab

Introduction Immune checkpoint inhibitors (CPIs) have changed the treatment landscape for many cancers, but also cause severe inflammatory side effects including enterocolitis. CPI-induced enterocolitis is treated empirically with corticosteroids, and infliximab (IFX) is used in corticosteroid-refra...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Hajir Ibraheim, Sophie Papa, Nick Powell, James L Alexander, James Larkin, Samra Turajlic, Andrew Furness, Julian P Teare, Paul Nathan, Dharmisha Chauhan, David J Pinato, Jessica Little, Raguprakash Ratnakumaran, Bhavisha Sheth, Muhammad Saheb Khan, Camellia Richards, Nikki Hunter, Kathleen McHugh, Julia Choy, Shanthini M Crusz, Lisa Pickering, Ally Speight, Anand Sharma
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	BMJ Publishing Group 2021-07-01
Saila:	Journal for ImmunoTherapy of Cancer
Sarrera elektronikoa:	https://jitc.bmj.com/content/9/7/e002742.full
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!